Luis Sanchez-Perez

List of Publications by Year
in descending order

57 papers	5,168 citations	136885 32 h-index	175177 52 g-index
59 all docs	59 docs citations	59 times ranked	7168 citing authors

#	Article	IF	Citations
1	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine, 2018, 24, 1459-1468.	15.2	437
2	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 2015, 519, 366-369.	13.7	429
3	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clinical Cancer Research, 2018, 24, 4175-4186.	3.2	402
4	Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature. Immunity, 2011, 35, 972-985.	6.6	392
5	Adoptively transferred effector cells derived from naÃ¯ve rather than central memory CD8 ⁺ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17469-17474.	3.3	348
6	EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. Clinical Cancer Research, 2014, 20, 972-984.	3.2	254
7	Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts. Cancer Research, 2010, 70, 6725-6734.	0.4	227
8	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research, 2017, 23, 1898-1909.	3.2	215
9	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clinical Cancer Research, 2019, 25, 4202-4210.	3.2	207
10	Type 17 CD8+ T cells display enhanced antitumor immunity. Blood, 2009, 114, 596-599.	0.6	196
11	Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nature Medicine, 2005, 11, 1073-1081.	15.2	137
12	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 270-275.	3.3	120
13	Toll-like Receptors in Tumor Immunotherapy. Clinical Cancer Research, 2007, 13, 5280-5289.	3.2	114
14	A simple method to cure established tumors by inflammatory killing of normal cells. Nature Biotechnology, 2004, 22, 1125-1132.	9.4	112
15	Monoclonal antibody blockade of IL-2 receptor Î± during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood, 2011, 118, 3003-3012.	0.6	104
16	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. PLoS ONE, 2014, 9, e94281.	1.1	99
17	Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. Journal of Clinical Neuroscience, 2014, 21, 189-190.	0.8	94
18	Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer. Cancer Research, 2007, 67, 11970-11979.	0.4	83

#	Article	IF	Citations
19	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Research, 2018, 78, 256-264.	0.4	82
20	Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies. Journal of Immunotherapy, 2011, 34, 343-352.	1.2	80
21	Potent Selection of Antigen Loss Variants of B16 Melanoma following Inflammatory Killing of Melanocytes In vivo. Cancer Research, 2005, 65, 2009-2017.	0.4	78
22	Oncolytic virusâ€"mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Science Translational Medicine, 2022, 14, eabn2231.	5.8	70
23	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. OncoImmunology, 2018, 7, e1434464.	2.1	69
24	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. Cancer Immunology Research, 2013, 1, 163-167.	1.6	61
25	Are BiTEs the â€œmissing linkâ€•in cancer therapy?. OncoImmunology, 2015, 4, e1008339.	2.1	59
26	Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. OncoImmunology, 2017, 6, e1256527.	2.1	59
27	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clinical Cancer Research, 2019, 25, 358-368.	3.2	51
28	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clinical Cancer Research, 2020, 26, 1141-1151.	3.2	43
29	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. OncoImmunology, 2015, 4, e994374.	2.1	41
30	Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas. Journal of Immunology, 2006, 177, 4168-4177.	0.4	39
31	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research, 2018, 24, 3611-3631.	3.2	39
32	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opinion on Biological Therapy, 2020, 20, 579-591.	1.4	37
33	Immunotherapy for malignant glioma. , 2015, 6, 68.		36
34	Delivery of CCL21 to Metastatic Disease Improves the Efficacy of Adoptive T-Cell Therapy. Cancer Research, 2007, 67, 300-308.	0.4	35
35	Emerging immunotherapies for glioblastoma. Expert Opinion on Emerging Drugs, 2016, 21, 133-145.	1.0	34
36	4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. Clinical Cancer Research, 2020, 26, 1349-1358.	3.2	34

#	Article	IF	Citations
37	Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. Journal of Clinical Neuroscience, 2018, 56, 163-168.	0.8	31
38	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. OncoImmunology, 2013, 2, e26757.	2.1	30
39	Antitumor Immunity Can Be Uncoupled from Autoimmunity following Heat Shock Protein 70â€"Mediated Inflammatory Killing of Normal Pancreas. Cancer Research, 2009, 69, 7767-7774.	0.4	28
40	First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. , 2020, 8, e000213.		21
41	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. OncoImmunology, 2014, 3, e944054.	2.1	19
42	Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care. Journal of Visualized Experiments, 2015, , .	0.2	17
43	Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach. Journal of Proteome Research, 2019, 18, 3032-3041.	1.8	14
44	BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunology, Immunotherapy, 2013, 62, 983-987.	2.0	13
45	Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics. , 2015, 3, 13.		13
46	CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. OncoImmunology, 2018, 7, e1502904.	2.1	11
47	Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. OncoImmunology, 2014, 3, e944059.	2.1	8
48	Promising vaccines for treating glioblastoma. Expert Opinion on Biological Therapy, 2018, 18, 1159-1170.	1.4	8
49	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. Journal of Clinical Oncology, 2019, 37, e13526-e13526.	0.8	8
50	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 205-211.	2.0	6
51	Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. Journal of Immunological Methods, 2013, 395, 14-20.	0.6	5
52	A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. Journal of Immunological Methods, 2018, 459, 90-93.	0.6	4
53	Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas. Current Drug Discovery Technologies, 2012, 9, 237-255.	0.6	4
54	Rescuing imperfect antigens for immuno-oncology. Nature Biotechnology, 2019, 37, 1002-1003.	9.4	2

#	Article	IF	Citations
55	IMST-44. LYMPHOPENIA ENHANCES THE EFFICACY OF CAR T CELLS DELIVERED LOCO-REGIONALLY IN THE BRAIN FOR THE TREATMENT OF GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi96-vi96.	0.6	0
56	DDIS-02. NOVEL BISPECIFIC ACTIVATOR OF MACROPHAGES FOR THE TREATMENT OF GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi69-vi69.	0.6	0
57	EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi84-vi84.	0.6	0